A dad from Cumbria has raised over £5,500 for a muscular dystrophy charity after finishing the National Three Peaks Challenge ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

The campaign to commemorate the work of the Muscular Dystrophy Association was created in partnership with agency Yes&.

The whir of circular saws and the thud of hammers broke the morning quiet in a North Seattle neighborhood on May 31, as seven ...

Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Repurposing existing therapies may help slow muscle weakness in patients with Duchenne muscular dystrophy, a new study ...

In many genetic diseases, a small error in the DNA code can have devastating effects. These errors, called nonsense mutations ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.

Dr. Tejal Aslesh Tailor is an accomplished neuroscientist and molecular biologist with years of expertise in preclinical ...